FEB 07, 2022 3:00 AM PST

Clinical Trial Demonstrates Beneficial Responses against a Rare form of Ovarian Cancer

WRITTEN BY: Katie Kokolus

Oncologists have identified five diverse subtypes of epithelial ovarian cancers: epithelial ovarian cancers as high-grade serous, endometrioid, clear-cell, mucinous, or low-grade serous. The subtypes differ in clinical characteristics, such as tissue of origin and molecular biology, and prognostic values, such as response to treatment and outcome.  

Low-grade serous ovarian carcinoma (LGSOC) is a rare type of ovarian cancer accounting for less than 10% of all ovarian cancers. LGSOC cases are often diagnosed in younger women (under 60 years). While this type of cancer is typically slow growing, it also tends to be resistant to chemotherapy. 

The Phase 2/3 multicenter, open-label trial was conducted internationally at 84 hospitals across the USA and UK to test the efficacy of MAPK inhibitor called trametinib. Patients recruited for the study were at least 18 years of age when diagnosed with LGSOC. The researchers randomly assigned patients to one of two treatment groups: trametinib or standard-of-care.  options for women diagnosed with LGSOC.  

One common characteristic of many cases of LGSOC is mutations in the Mitogen-Activated Protein Kinase (MAPK) pathway, which regulates proliferation, survival, and apoptosis in cancer cells. These findings have generated interest in targeting the MAPK pathway for the treatment of LGSOC. The promising results of one Clinical Trial (NCT02101788) studying such a therapeutic approach were recently published in The Lancet

The Phase 2/3 multicenter, open-label trial was conducted internationally at 84 hospitals across the USA and UK to test the efficacy of MAPK inhibitor called trametinib. Patients recruited for the study were at least 18 years of age when diagnosed with LGSOC. The researchers randomly assigned patients to one of two treatment groups: trametinib or standard-of-care.  Because this was a large-scale study conducted in multiple countries, the standard-of-care differed between participating centers.  Patients in the standard-of-care group received one of five chemotherapy treatments: paclitaxel, pegylated liposomal doxorubicin, topotecan, letrozole, or tamoxifen.

Once enrolled and assigned to a treatment group, doctors imaged tumors before the first treatment and every eight weeks for the first fifteen months.  After this, the time between imaging was reduced to every three months.

The Clinical Trial enrolled 260 patients assigning 130 to each treatment group.  Median progression-free survival, the time from randomization to disease progression or death, was 13 months in the trametinib group and about seven months in the standard-of-care group.  Further, the objective response rate, the proportion of patients with a clinical response, in the trametinib group was 26% compared to 6% in the standard-of-care group. 

The results of this Clinical Trial suggest that oncologists should consider trametinib for the treatment of women with LGSOC.  Further, trametinib could become a the standard-of-care treatment for this type of cancer. 

 

Sources: Hum Path, Can Biol Med, Cancer Network, Obstet Gynecol, Reprod Biol Endocrinol, The Lancet

 

 

About the Author
PhD
PhD in Tumor Immunology. I am interested in developing novel strategies to improve the efficacy of immunotherapies used to extend cancer survivorship.
You May Also Like
SEP 13, 2022
Immunology
How Cell 'Waste' Boosts Immune Cells' Fight Against Cancer
SEP 13, 2022
How Cell 'Waste' Boosts Immune Cells' Fight Against Cancer
It seems there is a lot more to lactate than we knew.
SEP 21, 2022
Cancer
Technology for Monitoring Tumors in Pre-Clinical Studies
SEP 21, 2022
Technology for Monitoring Tumors in Pre-Clinical Studies
Pre-clinical modeling, often using laboratory mice, is essential in developing life-saving therapies to treat cancer and ...
NOV 02, 2022
Clinical & Molecular DX
New Genetic Variants Identified as Risk Factors for Ovarian Cancer
NOV 02, 2022
New Genetic Variants Identified as Risk Factors for Ovarian Cancer
Ovarian cancer is a complex disease resulting from mutated cells in the ovaries. As the cells multiply, they can invade ...
NOV 11, 2022
Cancer
Veterans and Burn Pit Exposure
NOV 11, 2022
Veterans and Burn Pit Exposure
Today we recognize the Veterans Day holiday in the United States.  Each year, on November 11, Americans commemorate ...
NOV 17, 2022
Cancer
Anti-Aging Supplement Linked to Aggressive Breast Cancer
NOV 17, 2022
Anti-Aging Supplement Linked to Aggressive Breast Cancer
Vitamin B3, also known as niacin, is a generic name for a group of biochemical compounds, including nicotinamide ribosid ...
NOV 21, 2022
Cancer
More People Living with Metastatic Cancer
NOV 21, 2022
More People Living with Metastatic Cancer
Experts define metastatic cancer as cancer that spreads from the anatomical location where it started to a distant part ...
Loading Comments...